摘要 ：目的对4例汉族马凡综合征（MFS）患者的原纤蛋白-1（FBN1）基因进行突变筛查，探讨MFS与FBN1基因突变的关系。
Abstract : Objective To detect FBN1 mutation by screening FBN1 gene from 4 patients with Marfan syndrome(MFS)to investigate the correlation between the gene mutation and the MFS.
方法采集42例急性脑梗死患者血浆，测定其纤维蛋白原、d二聚体及纤溶酶原含量，并与对照组进行比较。
Methods Collecting the plasma of 42 acute cerebral infarction patients, the content of fibrinogen? D dimer and fibrinolysin was determined, and was compared with their content in control group.
降纤酶有明显降低血黏度、纤维蛋白原含量、红细胞聚集性、血小板聚集作用。
Defibrase can effectively reduce blood viscosity, content of fibrinogen, hemocyte aggregation and platelet aggregation.
结论：高血压、血纤溶系统活性升高、高水平纤维蛋白原、高同型半胱氨酸血症是脑梗死再发的重要危险因素。
Conclusion Hypertension, increased plasma PAI-1 activity, fibrinogen level and plasma Hcy level are the important risk factors in the recurrent cerebral infarction.
结论：精纯抗栓酶与降纤酶这两种蛇毒制剂的疗效相近，使用后使纤维蛋白原降低的作用时间均较短。
Conclusion: Ahalsantinfarctasel and Difibrinogenase have almost equal curative effect and both have the short effective duration to reduce the fibrinogen.
应用较为先进的检测手段，对84例恶性肿瘤患者血浆激肽释放酶原（PK）、纤溶酶原（PLG）、纤维蛋白原（FIG）进行测定，共100例次。
Plasma levels of prekallikrein (PK), plasminogen (PLG), fibrinogen (FIG) in 84 cases of malignant tumor were studied with an advanced method. Each item was measured 100 times.
结论：降纤酶治疗急性脑梗死疗效确切，能显著降低纤维蛋白原，改善全血黏度，降低致残率，不良反应少。
Conclusion: Defibrase can significantly decrease fibrinogen, improve whole blood viscosity, and decrease disability rate. With little side effect, it is effective on acute cerebral infarction.
结论降纤酶可降低纤维蛋白原、抑制红细胞聚集、降低血液粘度，从而改善微循环。
Conclusion Defibris could decrease fibrinogen, inhibit red blood cell accumulating, decrease viscosity of whole blood, as a result improved microcirculation.
结论降纤酶可降低纤维蛋白原、抑制红细胞聚集、降低血液粘度，从而改善微循环。
Conclusion Defibris could decrease fibrinogen, inhibit red blood cell accumulating, decrease viscosity of whole blood, as a result improved microcirculation.
应用推荐